Archives of Disease in Childhood (ADC) is an international peer-reviewed journal specialising in child health, covering the perinatal period through to adolescence. As an official journal of the Royal College of Paediatrics and Child Health, ADC provides paediatricians with the most recent, relevant and original research reports, commentaries, clinical and policy reviews, and education.

Every 3 months ADC publishes a Drug Therapy section which looks at different aspects of paediatric clinical pharmacology. Listed below are the five most cited articles in 2018 - 2019:

  • Developing a paediatric drug formulary for the Netherlands
  • Systematic review of the toxicity of short-course oral corticosteroids in children
  • Variation in paediatric hospital antibiotic guidelines in Europe
  • C-reactive protein point-of-care testing in acutely ill children: a mixed methods study in primary care
  • An increase in accident and emergency presentations for adverse events following immunisation after introduction of the group B meningococcal vaccine: an observational study

Read these and others here.
Members of the ESDPPP are encouraged to submit to the ADC Drug Therapy section. All articles across the pharmacology spectrum, from basic science (pharmacokinetics, pharmacodynamics), to randomised controlled trials, formulations, drug safety/pharmacovigilance, pharmacogenomics, pharmaco-epidemiology, and ethics/legal issues, will be considered if they have relevance to paediatrics.
ADC also publishes a drug therapy update section in the education section, that features reviews on many areas of therapeutics in paediatrics.

The next ESDPPP conference will be taking place in in Liverpool, UK, in 2021, and all abstracts accepted will be published in a supplement in ADC following the meeting.
Members who wish to consider writing a review article should contact Dan Hawcutt first ( 

Current articles from the ADC Journal

The last consumptive History is literally littered with examples of interventions which enjoyed a Warholian 15 min in the limelight. Without these ideas being aired though, there would have been no progression, no evolution of thinking. They should, therefore, be celebrated as milestones not derided as ideas barely worthy of the papyrus on which they were hatched. A century ago, with streptomycin still a generation away, only the most privileged would have been afforded the luxury of a sanitorium or better still an isolated alpine resort. In these settings, Lac Geneve shimmering in the background, the stubborn mycobacteria resistant to the usual liberal postural drainage manoeuvres and the plombage balls1 the more gung-ho thoracic surgeons advocated could be overcome or so it was believed. And belief in a treatment is after all, great fuel Biliary atresia It’s standard exam fare: early detection of biliary atresia...
>> Read More

1 Placental pharmacology studies to characterize the effects and disposition of pharmaceuticals: lessons from human tissues and cells for improving drug safety in pregnancy
The placenta plays a key role in maintaining a healthy pregnancy. In order to improve drug safety during pregnancy, it is therefore relevant to understand to which extent and at which rate drugs are transferred across the placenta and how pharmaceuticals may affect placental function. Translational and predictive pharmacology studies based on human tissues and cells are becoming increasingly important in characterizing the effects and disposition of pharmaceuticals. With regard to the placenta, such approaches may for example be readily combined with physiology-based pharmacokinetic (PBPK) modeling to predict fetal exposure of drugs, as well as placental tissue exposure in the clinic. In addition, placental tissue and cells can be used to study potential effects of drugs, as well. The current presentation, will highlight several studies that investigated the placental disposition and effects of both small and large molecule pharmaceuticals, as well as how such data can help to better understand the clinical pharmacology of therapeutics.
>> Read More

2 Pitfalls and opportunities for centralized TDM services: a Belgian singe-centre experience
Therapeutic drug monitoring (TDM) requires a multidisciplinary approach with different stakeholders (nurse, bio-analyst, pharmacist, pharmacologist, pharmacometrician, physician). In recent years, a pharmacist-guided TDM dosing advice service, mainly for anti-infective therapy, has been installed at the Ghent University Hospital, a tertiary hospital in Flanders, Belgium. From this experience, advantages, pitfalls and opportunities for centralized TDM services are being summarized. Together with the previous talk, this talk will serve as a basis for discussion with the audience.
>> Read More

3 The exposure to and efficacy of doravirine in pregnant women as assessed by physiologically-based pharmacokinetic modelling
Introduction Doravirine is currently not recommended for pregnant women living with HIV due to the lack of efficacy and safety data. Physiological changes during pregnancy can significantly decrease drug exposure, and, thereby, lower the efficacy. Awaiting clinical data, this study aimed to predict maternal and fetal doravirine exposure by integrating human placenta perfusion experiments with pregnancy physiologically-based pharmacokinetic (PBPK) modelling. Methods An existing and validated three-compartment PBPK model of doravirine for a healthy, non-pregnant population was modified to a 18-compartment PBPK model using Simcyp Simulator V20. The permeability-limited placenta model was included in the extended PBPK model to study placental transfer to the fetus. To parameterize the placenta model, ex vivo human cotyledon perfusion experiments were performed, and a mechanistic model was developed to derive placental transfer constants. The final pregnancy PBPK model was used to predict the maternal and fetal geometric mean (GM) concentration at 24h after dosing (C24h) at 26, 32 and 40 weeks of pregnancy. The GM C24h was compared to the target derived from in vivo exposure-response analysis of 0.23 mg/L. Results Perfusion experiments showed that doravirine extensively crosses the placenta. In comparison to non-pregnant women, the final pregnancy PBPK model estimated a maternal decrease in GM C24h of 55% for 40 weeks pregnancy. All predicted maternal GM C24h were <0.23 mg/L. Conclusions Substantially reduced maternal doravirine exposure was predicted during pregnancy, possibly resulting in impaired efficacy. Therapeutic drug and viral load monitoring are advised for pregnant women treated with doravirine, and the use should preferentially be restricted to clinical trials.
>> Read More